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INTRODUCTION
To successfully generate progeny virions and ensure productive replication, a virus must have access to the raw materials of its host cell. In response, the host cell must rapidly recognize the presence of the virus and employ a defense aimed at halting the infection. This arms race has resulted in an evolutionary track record of countless measures and countermeasures employed by both entities. In plants, arthropods, and nematodes, cells recognize the formation of double-stranded RNA (dsRNA) as a foreign structure indicative of virus infection (Kemp and Imler, 2009 ). This pathogen-associated molecular pattern (PAMP) is then processed in a variety of means to generate virus-specific small interfering RNAs (vsiRNAs) through an RNase III family of nucleases such as Dicer (Ding and Voinnet, 2007 ; Hutvá gner and Zamore, 2002; Sabin et al., 2013) . vsiRNAs are then loaded into an RNA-induced silencing complex (RISC) and subsequently used to guide it to complementary RNA (Ding and Voinnet, 2007) . This system, generally referred to as RNAi, is capable of cleaving viral mRNA in an enzymatic fashion and successfully inhibiting replication (Ratcliff et al., 1999; Zamore et al., 2000) . In response to this effective defense, plant and arthropod viruses have evolved antagonists to many aspects of the vsiRNA biogenesis pathway (Chao et al., 2005; Li et al., 2002; Nayak et al., 2010; Qi et al., 2012; van Rij et al., 2006) .
Interestingly, the cellular response to virus in mammals is also initiated by the detection of dsRNA or other foreign nucleic-acidbased structures (Bowie and Unterholzner, 2008) . However, unlike the situation with plants and arthropods, detection of dsRNA results in the culmination of a cytokine-mediated response. That is, PAMP detection in mammalian cells results in the activation of host kinases and transcription factors that result in the induction of type I and III interferons (IFN-I and IFN-III; Rauch et al., 2013) . IFN induction can act in both an autocrine and paracrine manner to promote the upregulation of hundreds of IFN-stimulated genes (ISGs) (Schoggins and Rice, 2011) . These genes work in concert to slow virus replication and provide the necessary time for the adaptive response to clear the infection. Included in the list of ISGs are host products that inhibit transcription, translation, and cellular transport, as well as genes involved in cell death and the release of chemokines to recruit immune cells to the site of infection (Schoggins and Rice, 2011) . As is the case for arthropod and plant pathogens that inhibit RNAi, viruses that infect mammals also have evolved proteins to antagonize many aspects of the IFN-I and IFN-III responses (Weber et al., 2003) .
Despite extensive research aimed at defining the mammalian response to virus infection, it still remains controversial whether RNAi is also a component of mammalian cells (Umbach and Cullen, 2009) . Evidence for RNAi in mammals includes the evolutionary conservation and utilization of small RNAs in the form of miRNAS (Bartel, 2004) . Like vsiRNAs, these 19-21 nt duplex RNAs are generated by RNase III nucleases, load into a RISC, and mediate posttranscriptional silencing (Bartel, 2004) . Given the conservation of this pathway and the required nucleases, it remains tempting to speculate that small RNAs, or the machinery itself, could function in an antiviral fashion. This concept is further supported by the fact that many dsRNA-binding proteins that antagonize virus detection in mammals also disrupt RNAi (Cullen et al., 2013; Fabozzi et al., 2011; García-Sastre et al., 1998; Haasnoot et al., 2007; Li et al., 2004; Prins et al., 2010) . Although this may reflect the fact that both systems are dependent on dsRNA detection and processing, a recent paper from our own group identified a bona fide inhibitor of small RNAs from poxviruses (Backes et al., 2012) , leading many to speculate that aspects of RNAi are indeed conserved in mammals.
Although limited evidence has supported a claim for RNAi in mammals, other experiments have strongly suggested that small RNAs are not a component of the vertebrate response to infection. For example, an engineered influenza A virus (IAV) lacking a dsRNA antagonist was shown to regain full virulence when administered to mice lacking IFN signaling capacity (García-Sastre et al., 1998) . If RNAi contributes to the mammalian response to virus infection, one would suppose that in an IFNindependent model system, lack of a dsRNA antagonist would still demonstrate some level of attenuation. Furthermore, incorporation of miRNA target sites into the genomes of countless viruses can induce attenuation, suggesting that these viruses have not needed to evolve countermeasures for small RNA silencing (tenOever, 2013) . The debate about RNAi in mammals, however, has further intensified with the advent of deep sequencing. Profiling of small RNAs from virus infection has demonstrated detectable pools of virus-derived small RNAs that could theoretically serve a role in RNAi, although these small RNA pools remain unchanged in the absence of Dicer and may actually be the by-product of ISGs such as RNaseL (Girardi et al., 2013; Parameswaran et al., 2010) . Although there is no clear consensus about how these small RNAs are generated and how they might function, the idea of mammalian RNAi recently gained significant traction in the scientific community following the characterization of a mutant nodavirus in both stem cells and immortalized fibroblasts Maillard et al., 2013) .
In an effort to formally address whether small RNAs significantly contribute to the mammalian response to virus infection, we generated a recombinant RNA virus with the capacity to disrupt either RISC-associated silencing or the IFN-mediated response. We demonstrate that we can give vesicular stomatitis virus (VSV) the capacity to eliminate RISC-associated small RNAs through the expression of vaccinia virus (VACV) VP55 (VSV-VP55) or block detection and subsequent IFN induction with the addition of IAV NS1 (VSV-NS1). Interestingly, we find that whereas VSV-NS1 replicates to higher titers in vivo, VSV-VP55 is attenuated. Furthermore, we find that attenuation is the result of an enhancement of the IFN response, in agreement with a recent report that miRNAs suppress the basal levels of antiviral transcripts (Seo et al., 2013) . Profiling the transcriptome of these infections also provided us with a comprehensive list of endogenous miRNA targets in the context of infection. To determine whether small RNAs contributed in the absence of the IFN response, we also administered VSV-VP55 to IFN-I and IFN-III receptor knockout mice. In this model system, virus attenuation of VP55 was lost, but the degradation of small RNAs still failed to increase overall virus titers. Taken together, these results indicate that the cellular response to virus infection is independent of small RNA silencing and is mediated exclusively by IFNs.
RESULTS

Small RNA Profiling of Virus-Infected Cells
Given the recent claims of RNAi in mammals, we sought to define the profile of small RNAs in the context of a spectrum of RNA virus infections. To this end, we cloned and deep sequenced total nucleotide pools in the range of 18-25 nt from cells infected with viruses from diverse families, including Orthomyxoviridae (IAV), Togaviridae (Sindbis virus [SV] ), Bornaviridae (Borna disease virus [BDV] ), and Rhabdoviridae (VSV ; Table S1 ). Small RNA sequencing reads were then consolidated and mapped to the respective virus genomes. For each virus infection, small RNA reads could be assembled into contigs with complete genomic coverage. In agreement with published literature, captured small RNA reads were readily detectable in all infections: 0.04%, 18.4%, 24.1%, and 0.05% of total small RNA reads mapped to the BDV, IAV, SV, and VSV genomes, respectively ( Figure 1A ; Donaszi-Ivanov et al., 2013; Girardi et al., 2013; Parameswaran et al., 2010; Sabin et al., 2013) . With the exception of VSV, virus-derived small RNAs failed to show a size preference indicative of RNAi activity ( Figure 1A ). Interestingly, when the size distribution of the VSV reads were plotted, the dominant size was 22 nt and there was an enrichment for sequence reads that mapped to the ends of the genome, reminiscent of the RNAilike activity recently described in mammalian cells (Figures 1A and 1B; Li et al., 2013) . However, it should be noted that these two most abundant VSV-derived small RNAs, which could be detected by small RNA northern blot, were Dicer independent ( Figures 1C and 1D ). Taken together, these data suggest that VSV may be a good model for obtaining additional evidence for or against a small RNA-mediated antiviral defense in mammals.
VSV Does Not Encode an Inhibitor of Small RNA Silencing To probe whether RNAi activity contributed to the cellular response to VSV infection, we next determined whether VSV encoded a suppressor of RNAi. Although VSV has been found to be sensitive to the RNAi system of arthropods and nematodes, we wanted to ensure that small RNAs could additionally target VSV in the context of our mammalian systems (Mueller et al., 2010; Wilkins et al., 2005) . To this end, we cloned four perfect target sites for the host hematopoietic cell-specific miR-142 as a 3 0 UTR of the Large (L) polymerase mRNA as previously described ( Figure 2A ; Kelly et al., 2010) . In agreement with published literature, we found that endogenous miR-142 processing and silencing potential were unperturbed in miR-142-expressing, macrophage-derived RAW cells in response to VSV infection, as titers were reduced by $2 logs when the miR-142 target sites were present ( Figure 2B ; Kelly et al., 2008 Kelly et al., , 2010 . In contrast, in the absence of miR-142, all viruses replicated to comparable levels ( Figures 2C and S1 ). Furthermore, insertion of a primary miRNA (miR-124) into VSV demonstrated that in the context of infection, the capacity to process hairpins was not compromised ( Figure 2D ). These results are in agreement with numerous published studies demonstrating the successful engineering of mammalian viruses to be silenced by or produce small RNAs in the mammalian host (Barnes et al., 2008; Cawood et al., 2009; Chua et al., 2013; Edge et al., 2008; Kelly et al., 2008; Langlois et al., 2012a Langlois et al., , 2012b Langlois et al., , 2013 Perez et al., 2009; Pham et al., 2012; Shapiro et al., 2010 Shapiro et al., , 2012 Varble et al., 2010 Varble et al., , 2013 . Taken together, these data suggest that RNA virus infection in mammalian cells results in large pools of small RNAs and that RISC function is not impaired during the early stages of infection.
Engineering an RNA Virus with the Capacity to Disrupt Small RNA Function We recently characterized a single VACV protein, termed VP55, that was both necessary and sufficient for the tailing of RISCassociated host miRNAs (Backes et al., 2012) . We found that VP55 indiscriminately added nontemplated adenosines specifically to RNAs that are associated with RISC, resulting in their rapid degradation (Backes et al., 2012) . Although we postulated that this activity stemmed from the evolutionary ancestry of entomopox viruses, which needed to block vsiRNAs, it remained possible that the virus-derived small RNAs themselves provided an inherent protection to virus in mammals, given the recent reports on such activity Maillard et al., 2013) .
To assess the contribution of small RNAs to the mammalian response to virus, we sought to insert VP55 into VSV to enable the virus to block small RNA-mediated silencing. To this end, we utilized a VP55 variant that was identified following mutagenesis studies and was found to have increased protein stability and activity ( Figure S2 ). VP55 T109A (herein referred to simply as VP55) was introduced between the Glycoprotein (G) and L RNA-dependent RNA polymerase (RdRp) genes using the canonical initiation and termination sequence of the Nucleoprotein (NP) gene ( Figure 3A ). Incorporation of VP55 into VSV (VSV-VP55), as well as a matched control virus with a comparable RNA insert but lacking an open reading frame (VSVctrl), was used to infect fibroblasts ( Figure 3B ). At $12 hr postinfection, VSV-VP55 demonstrated robust expression of the VACV protein.
Furthermore, this expression correlated with the capacity to tail and degrade exogenously expressed miR-124 while not impacting VSV leader RNA or the splicing RNA component U6 ( Figure 3C ).
To determine whether VSV-based expression of VP55 was sufficient to give the virus the capacity to block RNAi, we next transfected exogenous vsiRNAs directed against NP. To permit VP55-mediated tailing of the vsiRNA, we synthesized duplex See also Table S1 .
RNA lacking 2 0 -O-methylation, as this chemistry renders small RNAs resistant to VP55 tailing (Backes et al., 2012) . Transfection of unmodified 21 nt RNA duplexes composed of a scrambled sequence (scbl) or a complement of NP was followed by virus infection at a high multiplicity of infection (moi). At 10 hr postinfection, we analyzed whole-cell lysates by western blot using a polyclonal antibody that recognizes the viral glycoprotein (G), the viral matrix protein (M), and NP ( Figure 3D ). These analyses demonstrated that VSVctrl was highly susceptible to NP vsiRNA silencing, in contrast to VSV-VP55, which showed no evidence of NP targeting. Furthermore, sequencing of miR-146b, a miRNA that has been shown to be induced in response to virus infection (Taganov et al., 2006) , provided in vivo evidence of VP55-mediated polyadenylation ( Figure 3E ).
Determining the Interplay among miRNAs, RNAi, and RNA Virus Infection
In an effort to characterize the biology of VSV-VP55 independently of miRNA activity, we first compared multicycle growth curves for VSV-VP55 and VSVctrl in cells lacking Dicer ( Figures  4A and 4B ). Administering the virus at a low moi of 0.01 for a 48 hr period resulted in no significant change in viral protein levels ( Figure 4A ) or viral load, as both VSVctrl and VSV-VP55 replicated to comparable titers of 1 3 10 8 plaque-forming units (pfu)/ml ( Figure 4B ). These data demonstrate that in the absence of Dicer-generated small RNAs, VSV-VP55 and VSVctrl replicate at comparable levels. As a result, we subsequently used these two viruses to compare virus replication in Dicer-expressing fibroblasts ( Figures 4C and 4D ). Surprisingly, although previous studies have implicated host miRNAs in the direct silencing of VSV and RNAi activity in fibroblasts Otsuka et al., 2007) , we found that VSV-VP55 replication was indistinguishable from VSVctrl replication, again reaching approximately equal viral protein levels ( Figure 4C ) and titers (Figure 4D ). This was also true at earlier time points postinfection ( Figure S3 ). Taken together, these results suggest that small RNAs do not significantly impact the mammalian cellular response to virus infection in vitro.
Next, we chose to study a homogeneous population of physiologically relevant primary cells. As macrophages are an important cell type for in vivo replication of VSV, we decided to evaluate VSVctrl and VSV-VP55 in the context of a monocytederived primary macrophage cell population (Junt et al., 2007) . Ex vivo infection of bone-marrow-derived macrophages (BMMs) demonstrated comparable levels of infection as measured by plaque assay ( Figure 5A ). Not surprisingly, small RNA analysis of infected cohorts demonstrated a dramatic loss of host miRNAs, including miR-142, miR-146, miR-155, and miR-93, without impacting U6 RNA ( Figure 5B ). To ascertain how loss of small RNAs in primary macrophages impacted the cellular response to virus infection, we performed mRNA sequencing (mRNA-seq) and compared the transcriptomes of VSV infection in the presence and absence of small RNAs (Figure 5C ; Table S2 ). In agreement with recent reports concerning the indirect role of miRNAs in enhancing expression of host antiviral genes, we found the majority of transcripts that were impacted the most by the expression of VP55 were canonical ISGs (Seo et al., 2013) . Interestingly, this virus-induced miRNA ''targetome'' included numerous guanylate-binding proteins (Mx1, Mx2, Gbp5, Gbp7, and Gbp9), cytokines (TNFa, Cxcl10, and Ccrl2), pyrogens (Il1b), and known components of the antiviral sensing and signaling machinery (Rsad2, Ifih1, Aim1, Peli1, Csrnp1, Nlrc5, IRF1, Herc6, and Ddx60). Furthermore, the differential host expression of these genes in the absence of small RNAs could be independently corroborated by quantitative PCR (qPCR; Figure 5D ). Interestingly, this list includes transcripts such as PTGS2, IRF1, Pim1, Nos2, Fndc3a, and Peli1, which have already been independently implicated as miRNA targets (Guo et al., 2012; Liu et al., 2013a Liu et al., , 2013b Marquez et al., 2010; Shan et al., 2009; Thomas et al., 2012) . It is also noteworthy that we identified only two genes that were expressed at elevated levels in VSVctrl (Table S2 ), in agreement with the idea that miRNAs are negative regulators of transcription (Bartel, 2004) .
Defining the Contribution of Small RNAs In Vivo to the Host Response to Virus Infection
Given the lack of an in vitro phenotype following disruption of small RNA silencing (Figures 4 and 5) , we next sought to determine whether RNAi contributes to the physiological response to virus infection in vivo. To formally evaluate this possibility, we first examined whether in vivo infection of VSV resulted in the appearance of virus-specific small RNAs. To this end, we infected mice intranasally with VSVctrl or VSV-VP55 and deep sequenced small RNAs between 18 and 25 nt. The resulting data demonstrated the appearance of small RNAs comparable to those observed in fibroblasts, albeit at vanishing rare levels ( Figure 6A ; Table S3 ). Next, we investigated whether miRNA tailing and degradation could be observed in vivo. For this purpose, we chose to again ascertain the levels of miR-146. At 24 hr postinfection, total lung tissue from three independent animals demonstrated a significant loss of miR-146, demonstrating that, as previously reported (Backes et al., 2012) , VP55 is sufficient for targeting of small RNAs ( Figure 6B) .
In an effort to directly compare the contribution of small RNA silencing to IFN signaling in the context of virus infection, we generated a VSV strain to encode the NS1 protein of IAV, a potent inhibitor of RIG-I and the subsequent induction of IFN (Mibayashi et al., 2007; Pichlmair et al., 2006) . VSV-NS1 and VSV-VP55 were generated in an identical manner ( Figure 3A) . In vitro infections of VSV-NS1 demonstrated that it produced robust levels of NS1 and replicated to levels comparable to those ) ( Figure S4C ). However, whereas infections of these fibroblasts with either VSVctrl or VSV-VP55 resulted in robust induction of IFNb, VSV-NS1 demonstrated a dramatic loss of cytokine production, suggesting that NS1 was successfully targeting RIG-I ( Figure 6C ).
The induction of IFNb in vitro also inversely correlated to virus titers in both the lung and spleen ( Figure 6D ). That is, VSV-NS1, in the absence of IFNb induction, replicated to levels greater than 1 log when compared with VSVctrl virus. Furthermore, VSV-VP55, which demonstrated a modest increase in IFNb induction when compared with VSVctrl, was reduced by a log in vivo ( Figure 6D ). These results clearly illustrate the importance of IFN in the mammalian response to virus.
In an effort to address whether redundancy in the antiviral response systems failed to provide a fitness advantage to VSV-VP55 in vivo, we next repeated our studies in mice lacking both type I and III IFN systems ( Figure 6E ). To this end, we performed intranasal infection of IFN-I and IFN-III receptor knockout mice (Ifnar1 À/À /Il28r
) with VSVctrl, VSV-VP55, or VSV-NS1, but found no significant differences in viral titers in the lung or spleens of infected mice ( Figure 6E ). These data allow us to conclude that the enhanced titers of VSV-NS1 in wild-type mice was the result of muting the IFN response and, conversely, that the attenuation of VSV-VP55 was a result of an enhanced IFN response. Furthermore, the inability of VSV-VP55 to replicate to titers exceeding those of VSVctrl, even in the absence of IFN-I and IFN-III signaling, strongly suggests that a functional antiviral RNAi system is not a physiological contributor to mammalian antiviral defenses. 
DISCUSSION
The discovery that small RNAs have the capacity to influence protein levels posttranscriptionally ushered in a new era for biology (Fire et al., 1998) . Small RNA silencing can be observed in diverse biological processes, but predominantly involves pathogen defense, achieving ''transcriptional robustness,'' and maintaining distinct cellular lineages (Bartel and Chen, 2004; Ebert and Sharp, 2012; Nayak et al., 2013) .
The silencing potential of small RNAs is largely determined by the extent of their target complementarity. Therefore, genome-encoded miRNAs, which demonstrate only partial complementarity to target genes, have significantly less capacity to silence a transcript as compared with a vsiRNA, which would be perfectly complementary (tenOever, 2013) . For this reason, the concept of miRNAs contributing to the antiviral defenses of the cell is unlikely, because the modest repression coupled with the average half-life of cellular proteins would yield a limited overall impact during the context of acute virus infection. This is not the case for viruses that can persist (Gottwein and Cullen, 2008) . However, while miRNAs may not have the capacity to directly silence a viral message, the cell's capacity to process and utilize small RNAs has led to extensive speculation as to whether mammals are capable of eliciting an RNAi response. The idea of RNAi in mammals has been further supported by reports that viral dsRNA-binding proteins such as NS1, E3L, and VP35 can inhibit RNAi activity in both plants and arthropods (Bucher et al., 2004; Chou et al., 2007; Delgadillo et al., 2004; Li et al., 2004) . Furthermore, with the advent of deep sequencing, small RNA profiling has demonstrated that many virus infections result in the accumulation of genome-derived small RNAs, although in the case of mammals, these RNAs were found to be independent of Dicer (Parameswaran et al., 2010) . It is also noteworthy that Drosha has been reported to translocate from the nucleus to the cytoplasm in response to virus infection, but this activity did not correlate with the appearance of virus-specific RNAs (Shapiro et al., 2014) .
Most recently, two reports demonstrated that RNase III generated vsiRNAs against EMCV and a mutant nodavirus Maillard et al., 2013) . Interestingly, one of these studies suggested that RNAi was only a component of undifferentiated stem cells and that this activity diminished as the cells became responsive to IFN (Maillard et al., 2013) . In contrast, the second study found similar evidence for small RNA processing in terminally differentiated hamster fibroblasts . Together, these studies put forth some provocative data hinting at the existence of an RNAi pathway in mammals, but neither study demonstrated that the small RNAs detected mediated viral cleavage in an antiviral fashion . Furthermore, both studies utilized multifunctional virus antagonists (B2 of nodavirus and VP35 of Ebola), which have been shown to profoundly impact the mammalian host response to virus independently of small RNAs (Petrillo et al., 2013; Prins et al., 2010) . Given the importance of this question, we sought to formally evaluate the mammalian response to virus to determine whether RNAi is a physiological contributor to this process. To this end, we generated two virus model systems using a vaccine strain of VSV that is exquisitely sensitive to both IFN and RNAi (Mueller et al., 2010; Vogel and Fertsch, 1987; Wilkins et al., 2005) . For this, we inserted the only known mammalian virus protein capable of degrading small RNAs loaded into a RISC (VACV VP55) or a RIG-I antagonist of IAV (IAV NS1). Insertion of VP55 or NS1 into VSV provided us with a unique tool to ascertain the physiological role of small RNAs or IFN, respectively. Interestingly, a VSV strain capable of eliminating host small RNAs was found to replicate at a diminished capacity as compared with control virus, in contrast to VSV-NS1, which replicated to levels that exceeded 1 log over control. Although these results argue against a role for RNAi in mammals, they are in agreement with a recent publication concerning virus-induced polyribosylation and shutdown of RISC, which also would argue against RNAi functioning in mammals during times of stress (Leung et al., 2011; Seo et al., 2013) . Transcriptome profiling of VSV-VP55 and VSVctrl infections supports the idea that loss of RISC function results in a significant increase in a broad range of transcripts, including a subset of ISGs. It should be noted that these data do not suggest that loss of miRNAs leads to a specific upregulation in this class of genes, but rather that in the context of infection, changes in ISG levels would be most prominent. Lastly, to determine whether RNAi perhaps contributed a secondary response to IFN that would be masked in the context of wild-type mice, we also tested our engineered viruses in mice lacking both type I and III IFN systems. These results also demonstrated that all viruses replicated to comparable levels, suggesting that the small virus-derived RNAs that can be detected in vivo are unlikely to contribute to the antiviral response under physiological conditions.
Although it is difficult to prove the absence of a biological activity, we believe our results put forth a strong argument against a physiological RNAi antiviral response in mammals. In addition to the results presented here, other studies have suggested a lack of small RNA silencing in our antiviral defenses. Perhaps the greatest support for this idea comes from the fact that viruses can be targeted through the exploitation of host miRNAs (tenOever, 2013) . This technique, which has been employed by Table S2. countless groups and in a wide range of viruses, requires RISC function to be intact during infection, at least for the initial hours preceding viral transcription. If RNAi in mammals is detrimental to virus infection, one would postulate that this aspect of RISC function would be antagonized by viruses as is the case for IFN. In addition to this anecdotal support, other aspects of mammalian biology suggest that RNAi is unlikely to contribute to the antiviral response. First, it has been demonstrated that expression of an RdRp in mammalian cells is sufficient to induce IFN-I in the absence of infection (Yu et al., 2012) . RdRp function in plants and worms is used to generate and amplify vsiRNAs (Carthew and Sontheimer, 2009; Schwach et al., 2005) . Although flies maintain an RNAi response in the absence of vsiRNA amplification or an RdRp, they compensate for this by modifying their small RNAs via 2 0 -O-methylation to extend the half-life of the small RNAs and use them in a systemic manner (Ameres et al., 2010; Saleh et al., 2009 ). However, in contrast to flies and plants, mammals only utilize this chemistry on Piwi-interacting RNAs in stem and germ cells (Aravin and Hannon, 2008) . Taken together, these studies suggest that the evolution of chordates involved a dramatic modification of how our cells respond to virus infection.
It is noteworthy, however, that while RNAi does not perform a physiological role in the antiviral response, this lack of interplay provides us with some valuable resources. One example of such a resource is the VSV-VP55 virus used in these studies. ) were infected intranasally with VSVctrl, VSV-VP55, or VSV-NS1 (1 3 10 4 pfu). At 48 hr postinfection, the lungs and spleens were analyzed by plaque assay. Statistical analysis was performed on indicated samples using a two-tailed, unpaired Student's t test. Data are considered significant if the p value is <0.05. See also Figure S4 and Table S3 .
Transcriptome profiling of infected cells allowed us to accurately map the miRNA targetome in infected cells from an in vivo infection. The addition of VP55 to more inert vectors, such as a lentivirus or adenovirus, may also be useful for similar studies. Furthermore, the lack of interplay between small RNAs and mammalian viruses allows one to exploit the small RNA pathway to control tropism, produce vaccines, or create layers of biocontainment (Lauring et al., 2010; tenOever, 2013) . In addition, the lack of interplay between mammalian viruses and the small RNA machinery also makes these vectors ideal for the delivery of small RNAs . The ability to deliver siRNAs is a critical need in the medical field, and the recent discovery that RNA viruses can also be engineered to encode siRNAs and utilize the small RNA host machinery makes this a provocative option for future therapeutics. (Calabrese et al., 2007) . For the generation of BMMs, femurs were removed from naive mice and BM cells were cultured for a minimum of 10 days in RPMI containing 20% (vol/vol) FBS, L-glutamine, and 30% (vol/vol) conditioned media from L929 cells. VSV142T and VSVscbl were generated as previously described (Kelly et al., 2008) . VSV expressing VACV VP55 (VSV-VP55), IAV NS1 (VSV-NS1), and a same-size RNA insert not encoding for an open reading frame (VSVctrl) were generated and rescued as previously described (Stojdl et al., 2003) . Generation of VSV expressing miR-124 has been described elsewhere (Langlois et al., 2012a) . Infections with VSV (strain Indiana), VACV (strain Western Reserve), SV, and IAV (A/PR/8/34) were performed at the indicated moi at 37 C.
In Vivo Infections C57BL/6 mice were purchased from Taconic. Ifnar1
À/À /Il28r À/À mice have been described elsewhere (Mordstein et al., 2010) . Mice were anesthetized with isoflurane and infected intranasally with 1 3 10 4 (Ifnar1
7 (C57BL/6) pfu of VSV. Lungs and spleens were removed on the indicated days postinfection and homogenized in 500 ml PBS for analysis by plaque assay or in 1 ml Trizol for analysis by northern blot and small RNA deep sequencing. All experiments involving animals were done in accordance with the guidelines of the Mount Sinai School of Medicine Institutional Animal Care and Use Committee.
Western Blot and Small RNA Northern Blot Western blots were generated from total protein separated on a 12% SDS-PAGE gel. Resolved protein was transferred to nitrocellulose (Bio-Rad), blocked for 1 hr with 5% skim milk at 25 C, and then incubated with the indicated antibody overnight at 4 C. The polyclonal VSV antibody (a kind gift from Dr. J. Bell, University of Ottawa, Ottawa, Canada) and VACV VP55 antibody (a kind gift from Dr. R. Condit, University of Florida, Gainesville, FL) were used at a 1:5,000 dilution. The VACV E3L antibody (NR-4547; BEI Resources), IAV NS1 antibody (1A7; MSSM Hybridoma Center), and anti-pan-actin antibody (Neomarkers) were used at a 1:2,000 dilution. Secondary mouse and rabbit antibodies (GE Healthcare) were used at a 1:5,000 dilution for 1 hr at 25 C.
All antibodies were diluted in 5% skim milk. Immobilon Western Chemoluminescent HRP substrate (Millipore) was used as directed. Small RNA northern blots and probe labeling were performed as described previously (Pall and Hamilton, 2008 VSV Plaque Assay VSV was inoculated into the indicated cell lines containing serum-free DMEM for 1 hr. The inoculum was then aspirated off and replaced with complete medium for the indicated times. Briefly, cells were infected with VSV (moi as indicated) and 0.25 ml of supernatant was removed at the indicated times. Supernatant was plaqued in Vero cells in serial dilutions in triplicate in 1% methylcellulose. Plaques were counted at 3 days postinfection. Error bars represent the SD (n = 3) and p values were calculated based on a two-tailed t test. 
qRT-PCR
RNAi and Transfections
Chemically unmodified anti VSV-NP siRNA (IDT; 5 0 -TTTCCCGATGTTTATT CC-3 0 ) was transfected into BHK cells in suspension using RNAiMAX (Invitrogen). Cells were infected with VSV at 6 hr posttransfection and harvested at 10 hr postinfection. Plasmids were transfected into cells in suspension using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions.
Small RNA Deep Sequencing and mRNA-Seq Analysis Deep sequencing was performed on wild-type murine fibroblasts (18-25 nt fraction) infected with VSV, SV, or IAV at an moi of 1 for 12 hr on C6 glial cells persistently infected with BDV (He/80) (18-25 nt fraction) or on mouse lungs infected with VSVctrl or VSV-VP55 (18-25 nt fraction). Isolation, purification, and amplification of small RNA species were performed as previously described (Langlois et al., 2012b) . Small RNA libraries were generated as previously described (Pfeffer et al., 2004) . Briefly, total RNA from indicated samples was isolated using TRIzol (Invitrogen) and spiked with radiolabeled size markers prior to size fractionation on a 12% denaturing Tris-urea gel (SequaGel; National Diagnostics). RNA was separated by electrophoresis on a 15% TBE-urea gel, and RNA molecules $17-26 nt were excised and eluted from the gel fragments. Following ethanol precipitation, small RNA-seq libraries were produced using the Small RNA Sample Prep v1.5 kit (Illumina) according to the manufacturer's instructions. RNA-seq was performed on BMMs infected with VSV at an moi of 5 for 10 hr. RNA extracts were prepared using standard mRNA-seq protocols (Cat. No. 1502062; Illumina) . Briefly, mRNA was isolated from 1 mm of RNA using sera oligo-dT beads. This was then used for cDNA synthesis with SuperScript II reverse transcriptase (Life Technologies). This was followed by second-strand synthesis, end repair, A-tailing, ligation, and PCR using the Illumina Truseq kit. Amplification of the cDNA library was checked using the Bioanalyzer DNA 1000 Assay. mRNA-seq libraries were clustered with cBOT (Illumina) and then run on HiSeq (Illumina) for 100-base single-read sequencing.
Statistical Analysis
Statistical analysis was performed on the indicated samples using a twotailed, unpaired Student's t test. Data are considered significant if the p value is < 0.05. 
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